A Study to Assess the Clinical Effects of Navarixin in Participants With Psoriasis (MK-7123-009)
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
This study was conducted: 1) to assess the clinical effect of Navarixin on the Psoriasis
Activity and Severity Index (PASI), 2) to determine the effects of Navarixin on the
Physician's Global Assessment (PGA), 3) to evaluate the safety and tolerability of Navarixin,
and 4) to determine the multiple-dose pharmacokinetics of Navarixin.